|Bid||6.03 x 3000|
|Ask||6.09 x 900|
|Day's Range||6.00 - 6.22|
|52 Week Range||2.25 - 7.35|
|Beta (5Y Monthly)||-0.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2021 - Nov 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.49|
Subscribe to Yahoo Finance Plus to view Fair Value for BLULearn more
BELLUS (BLU) completes enrollment in the mid-stage studies for refractory chronic cough and chronic pruritus associated with atopic dermatitis.
LAVAL, Quebec, September 23, 2021--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that the Company has completed patient enrollment in the Phase 2b SOOTHE clinical trial of BLU-5937 in refractory chronic cough ("RCC") and the Phase 2a BLUEPRINT clinical trial of BLU-5937 in chronic prur
Investors need to pay close attention to BELLUS Health (BLU) stock based on the movements in the options market lately.